Regulatory approval

Published by the Health Canada.

Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

This is written in the approval document as:

TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

Citation

Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib